Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

European Research Council grant · Running

ARACHNID Automated canceR-on-A-CHip orgaN-specific metastatIc spreaD

Coordinator
Universita Degli Studi Di Padova, Italy
Runs
1 July 2024 to 31 December 2025
Status
Running
EU funding
€150k
Total cost
—
Partners
2 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101158013

What the project is doing

In the project's own words, from its summary on CORDIS.

Despite the improvements in cancer treatments, diagnostic tools and prevention/early detection strategies, cancer is still a major public health burden as one of the 6 leading causes of death worldwide. In 2020, 90% of the 10 million deaths registered out of 19.3 million new cancer diagnoses were associated not with primary tumors but with the secondary ones generated by the metastatic process. The complex time-dependent chain of events and cascades of biophysical and biochemical factors regulating tumor metastasis cannot be replicated using conventional in vitro cell models (such as transwell invasion and scratch/wound healing assays) nor in vivo animal models.

The scientific and medical communities are striving to better understand the steps of metastatic spreading to devise strategies to stop its occurrence, especially in pediatric oncology, as in the case of Neuroblastoma, the most common and difficult to treat among tumors of preschool age (15% of pediatric oncology deaths). To solve these limitations we propose ARACHNID, a unique, multiplexed, automated, and increased-throughput multi-organ on a-chip platform conceived around the complex process of cancer metastatic spread.

The project's potential for breakthrough innovation resides in its unique capabilities, promising to accelerate research, reduce costs, and contribute to the development of more effective cancer treatments. The ARACHNID project aims to explore and prove the technical-commercial potential of our proprietary tumor-metastasis-on-a-chip (TMOC) platform, starting from pediatric tumors and extending the application to adult cancers, involving Biogenera, biotechnological SME operating the pharma NB domain, as a testbed and early adopter.

Topics

Who is involved

OrganisationCityCountryRole
Universita Degli Studi Di PadovaPadovaItalyCoordinator
Biogenera SpABolognaItalyParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI